Tech Company Financing Transactions
Rain Therapeutics Funding Round
Rain Therapeutics, based in Newark, secured $18.4 million from BVF Partners, Auckland UniServices and Perceptive Advisors.
Transaction Overview
Company Name
Announced On
5/22/2018
Transaction Type
Venture Equity
Amount
$18,400,000
Round
Series A
Investors
Proceeds Purpose
Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
8000 Jarvis Ave. 204
Newark, CA 94560
USA
Newark, CA 94560
USA
Phone
Website
Email Address
Overview
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Avanish Vellanki
Co-Founder
Robert Doebele
Browse more venture capital transactions:
Prev: 5/22/2018: Bestow venture capital transaction
Next: 5/22/2018: Outreach venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs